Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours

Lisi Elizabeth Lim; David L Chan; David Thomas; Yang Du; Gary Tincknell; Anna Kuchel; Alexander Davis; Dale L Bailey; Nick Pavlakis; Gabrielle Cehic; William Macdonald; David Wyld; Eva Segelov

doi:10.18632/oncotarget.27659

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours

Oncotarget. 2020 Jul 7;11(27):2636-2646. doi: 10.18632/oncotarget.27659.

Authors

Lisi Elizabeth Lim¹, David L Chan^{2

3}, David Thomas⁴, Yang Du⁵, Gary Tincknell⁴, Anna Kuchel^{6

7}, Alexander Davis², Dale L Bailey^{2

8}, Nick Pavlakis^{2

8

9}, Gabrielle Cehic^{5

10}, William Macdonald¹¹, David Wyld^{6

7}, Eva Segelov^{1

12}

Affiliations

¹ Department of Medical Oncology, Monash Health, Melbourne, Australia.
² Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
³ Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, Australia.
⁴ Department of Medical Oncology, St. George Hospital, Sydney, Australia.
⁵ Department of Nuclear Medicine, The Queen Elizabeth Hospital, Adelaide, Australia.
⁶ Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
⁷ Faculty of Medicine, University of Queensland, Brisbane, Australia.
⁸ Sydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, Sydney, Australia.
⁹ Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
¹⁰ University of South Australia, Adelaide, Australia.
¹¹ Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, Australia.
¹² Faculty of Medicine, Monash University, Melbourne, Australia.

Abstract

Background: Peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours (GEP NETs), Although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor. Use of PRRT for lung (bronchial) NET, specifically typical and atypical carcinoid (TC, AC), has been reported only in small retrospective case series. This multicentre study adds to the evidence regarding utility of PRRT for lung NETs.

Materials and methods: A retrospective chart review of patients with TC and AC who received ¹⁷⁷Lu-dotatate PRRT between January 2002 and June 2019 in six hospitals across Australia was undertaken. Data regarding demographics, efficacy and toxicity was evaluated at each site by the treating clinician.

Results: Forty-eight patients (32 AC, 15 TC, 1 unclassified) received a median of four ¹⁷⁷Lu-dotatate treatments. There was a median of one prior line of systemic treatment (range: 0-3). The response rate to ¹⁷⁷Lu-dotatate was 33%, with a median overall survival of 49 months (range of 3-91), at a median follow up of 33 months. This compares favourably with GEP NET. Overall toxicity was recorded as modest.

Conclusions: ¹⁷⁷Lu-dotatate PRRT in patients with lung NETs is used in real world practice, where it appears well-tolerated with some efficacy. Further evidence could be obtained through a global prospective clinical or registry trial.

Keywords: atypical; carcinoid; lung; neuroendocrine; peptide receptor radionuclide therapy.